Cancer Immunotherapy News and Research

RSS

ELRIG announces Drs Stephen Ward and Annarita Miccio as keynote speakers for Cell and Gene Therapy 2026

ELRIG, a not-for-profit, volunteer-led organization dedicated to the global drug discovery community, today announced the keynote speakers for Cell and Gene Therapy 2026. Drs Stephen Ward (Cell and Gene Therapy Catapult) and Annarita Miccio (Imagine Institute) will lead the inaugural two-day event taking place at Hinxton Hall in Cambridge, UK from 9-10 March.

20 Jan 2026

Web-based cytometry atlas reveals immune signatures across pancreatic cancer treatments

Oncologists have achieved some immune system responses in patients with pancreatic cancers using various combinations of vaccines and immune checkpoint inhibitor drugs, but it's not always clear which therapy is inducing what type of response.

16 Jan 2026

Bacterial metabolite enhances immune checkpoint therapy against lung cancer

UF Health Cancer Institute researchers have discovered a small compound produced naturally by gut bacteria that doubled the response to lung cancer immunotherapy treatment in mice and can now be made into a drug for testing in humans.

14 Jan 2026

Novel antibody shows promise in overcoming resistance to cancer immunotherapy

According to a Phase I study led by researchers at The University of Texas MD Anderson Cancer Center, published today in Nature Medicine, the novel monoclonal antibody linavonkibart demonstrated the potential to overcome treatment resistance to anti-PD-1 immune checkpoint inhibitors in multiple cancer types.

13 Jan 2026

Targeting IDO1 for cancer: Novel degraders show promise in preclinical studies

Cancer cells employ a variety of strategies to evade the immune system, and modern immunotherapies aim precisely at these escape mechanisms.

9 Jan 2026

UVA researcher wins $700,000 for promising ovarian cancer research

Promising ovarian cancer research by Melanie Rutkowski, PhD, at the University of Virginia Comprehensive Cancer Center has won $700,000 in support from the Victoria's Secret Global Fund for Women's Cancers in partnership with Pelotonia and AACR, the American Association for Cancer Research.

8 Jan 2026

Cornell-developed nanoparticles improve cancer immunotherapy effectiveness

A class of ultrasmall fluorescent core-shell silica nanoparticles developed at Cornell is showing an unexpected ability to rally the immune system against melanoma and dramatically improve the effectiveness of cancer immunotherapy, according to a new study led by Weill Cornell Medicine and Cornell Engineering researchers.

7 Jan 2026

Newly discovered molecules accelerate the removal of immune-modulating enzyme

Cells have a remarkable housekeeping system: proteins that are no longer needed, defective, or potentially harmful are labeled with a molecular "tag" and dismantled in the cellular recycling machinery.

7 Jan 2026

Vitamin A derivative suppresses immune response and cancer vaccine efficacy

Scientists at the Princeton University Branch of the Ludwig Institute for Cancer Research have identified novel mechanisms by which a metabolic derivative of vitamin A-all-trans retinoic acid-compromises both the body's normal anti-cancer immune response and, in a different context, the efficacy of a promising type of cancer vaccine.

5 Jan 2026

Study uncovers how aggressive breast cancer cells escape immune defenses

With a new study in the journal Science Bulletin, researchers at Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University have discovered a new way that aggressive breast cancer cells escape the immune defenses.

1 Jan 2026

Precision immunotherapy for TRBC2-positive T-cell malignancies

Researchers at the Johns Hopkins Kimmel Cancer Center's Ludwig Center developed a new treatment that selectively targets TRBC2-positive T-cell cancers, expanding a precision approach they established in 2024 for TRBC1-positive tumors.

22 Dec 2025

Study identifies TAK1 gene as a key brake on cancer immunotherapy

Australian researchers have discovered that the TAK1 gene helps cancer cells survive attack from the immune system, revealing a mechanism that may limit the effectiveness of immunotherapy treatments.

19 Dec 2025

Scientists engineer AbLecs to overcome cancer's immune evasion tactics

Researchers at MIT and Stanford University have developed a new way to stimulate the immune system to attack tumor cells, using a strategy that could make cancer immunotherapy work for many more patients.

16 Dec 2025

Chemotherapy may reduce HIV-infected T cells

Advancements in HIV/AIDS research, drug development and clinical practice since the 1980s have made it possible for people living with HIV to lead long, productive lives and keep the virus in check at undetectable levels and nontransmissible as long as therapy is maintained.

15 Dec 2025

New insights explain the Treg paradox in colorectal cancer

In most solid tumors, high numbers of regulatory T (Treg) cells are associated with poorer outcomes because they dampen the immune system's ability to fight against a tumor.

15 Dec 2025

Immune checkpoint inhibitors can trigger rare immune thrombocytopenia in cancer patients

Researchers led by investigators at Mass General Brigham have published valuable information about a rare but serious complication of anti-cancer immunotherapy, providing the first large-scale description of its risk factors and clinical course, and underscoring the importance of early diagnosis and treatment.

12 Dec 2025

Review highlights emerging role of tumor MHC-II in shaping cancer immunotherapy outcomes

Cancer immunotherapy has transformed cancer treatment, yet many patients experience limited or short-lived responses due to immune evasion, tumor heterogeneity, and immune-related adverse events.

11 Dec 2025

Dietary restriction boosts antitumour immunity by rewiring T cell metabolism

Dietary restriction reshapes CD8+ T cell metabolism by increasing ketone body–driven acetyl-CoA production, preventing terminal exhaustion and enhancing tumour control in mice. This metabolic reprogramming also boosts responsiveness to PD-1 blockade, suggesting a potential strategy to improve cancer immunotherapy.

10 Dec 2025

Generative AI aids discovery of ISM3830's novel scaffold

Casitas B-lineage lymphoma-b (CBLB) is an E3 ubiquitin–protein ligase that functions as an intracellular checkpoint and master negative regulator of T‑cell and natural killer (NK) cell activation, playing a central role in modulating T-cell activation and immune tolerance, and its inhibition enhances T cells and NK cells function, also provides a strategy for the function restoration of exhausted T cells.

1 Dec 2025

New research questions reliability of macaque models for TIGIT-targeted cancer treatments

A new study published in the Journal of Biological Chemistry from UC Davis Comprehensive Cancer Center finds that TIGIT, an immune checkpoint receptor targeted by cancer immunotherapy drugs, triggers a different response in rhesus macaques compared to humans.

24 Nov 2025